Background {#Sec1}
==========

Type 2 diabetes mellitus (T2DM) is a long-term metabolic disorder caused by both genetic and environmental factors. The defects in insulin secretion or function (or both) can cause disorder in carbohydrates, proteins, fats, electrolytes, and water metabolism \[[@CR1]--[@CR3]\]. It is clinically characterized by chronic persistent hyperglycemia and high volatility. T2DM patients also tend to be associated with a series of chronic complications, such as nerve, blood vessel and gastrointestinal tract defects including intestinal mucosal barrier damage, seriously affecting the life quality \[[@CR4], [@CR5]\]. According to the latest statistics from the National Vital Statistics System, diabetes is the seventh of the top ten causes of death in the United States in 2016 \[[@CR6]\].

The intestine is an important organ that should not be omitted during the treatment of DM \[[@CR7]--[@CR9]\]. The intestinal mucosal barrier prevents the translocation of bacteria and endotoxins into blood and lymph circulatory systems under normal physiological conditions. Dysregulation of intestinal mucosal barrier function would increase the permeability to the intestinal pathogens and endotoxins, which cause infection or inflammation \[[@CR10], [@CR11]\]. Previous studies suggested that the low-grade inflammatory state of patients with T2DM was possibily related to intestinal endotoxin \[[@CR12], [@CR13]\]. On the other hand, disorder of intestinal microflora composition is associated with the intestinal mucosal barrier damages \[[@CR14], [@CR15]\], which leads to nonspecific inflammatory, and in turn aggravates insulin resistance and T2DM metabolism disorders through the NF-κB pathway and JNK signal transduction pathway \[[@CR16]--[@CR18]\]. Therefore, the intestinal mucosal barrier function of patients with T2DM should be carefully monitored.

Currently, levels of the serum D-lactic acid, diamine oxidase (DAO), and endotoxin, which reflect the permeability of intestinal mucosa and bacterial translocation, are used to determine the intestinal mucosal barrier function in clinical practice \[[@CR19], [@CR20]\]. For patients with T2DM, glycemic monitoring (including short- and long-term blood glucose level fluctuations, as well as average blood glucose levels) is substantial. Studies have shown that persistent hyperglycemia can lead to intestinal mucosal barrier damage \[[@CR5]\], however, the relationship between fluctuation of blood glucose level and intestinal mucosal barrier damage remains unclear. Therefore, this study aimed to investigate the relationship between glycemic control and intestinal mucosal barrier dysfunction in patients with T2DM.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

We recruited 66 patients diagnosed with T2DM from September 2017 to June 2018. All patients included in the study met the diagnostic criteria of the 2018 AACE/ACE Consensus Statement: Comprehensive Management of T2DM \[[@CR21]\]. And their eating pattern were controlled according to the suggestion of 'Standards of Medical Care in Diabetes' in 2014 \[[@CR22]\]. The control group was composed of 33 healthy volunteers who were recruited in a 2:1 ratio according to the patients' sex and age. All subjects with digestive diseases, chronic malnutrition, malignant tumors, and intestinal infections which can inhibit the intestinal mucosal barrier function within 2 weeks were excluded.

The study protocol was approved by the Ethics Review Board of Jiading District Central Hospital (2017-ZD-03). All subjects were anonymized. All subjects signed informed consent form.

Study methods {#Sec4}
-------------

For all subjects included, the fasting venous blood sample was collected, the fasting blood glucose was examined, and the functionality of intestinal mucosal barrier of subjects were determined by the serum D-lactic acid, DAO, and endotoxin. Patients with T2DM were further divided into the low-value group (\< 12.31u/l, *n* = 33) and high-value group (≥12.31u/l, n = 33) based on the median endotoxin levels. For the patients with T2DM, clinical characteristic were collected \[DM duration, body mass index (BMI), history of hypertension, use of drugs (such as insulin and metformin etc.), smoking history, and family history of DM\]. The abnormal fasting blood glucose, 2 h blood glucose level after breakfast, glycated hemoglobin (HbA1c), and glycated albumin (GA) of patients were also examined at the first day of enrollment. The daily blood glucose level (before breakfast (A), 2 h after breakfast (B), before lunch (C), 2 h after lunch (D), before dinner (E), 2 h after dinner (F), and before sleep (G)) was monitered by active blood glucose meter (Accu-Chek®, Germany) using the finger capillary blood samples. Short-term glycemic excursions, including the magnitude of postprandial glucose excursion (PPGE), the largest amplitude of glycemic excursions (LAGE), and the standard deviation of blood glucose (SDBG) within 1 day were calculated by:
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LAGE = D (maximum glycemic value) - A (minimum glycemic value);
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Functionality of the intestinal mucosal barrier {#Sec5}
-----------------------------------------------

The functionality of the intestinal mucosal barrier was determined using the DAO/lactic acid/bacterial endotoxin combined test kit (enzymatic method; Beijing Zhongsheng Jinyu Diagnostic Technology Co., Ltd.), supporting by the JY-DLT intestinal barrier function biochemical indicator analysis system. The experiments were undergone according to the protocols suggested by the manufacturer and conducted within 4 h after serum extraction.

Statistical analysis {#Sec6}
--------------------

Statistical analysis was done using the SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). Normally distributed data were expressed in mean ± standard deviations (SD) and compared using Student's *t* test; otherwise was indicated as Median (Q1\~Q3) and compared using the non-parametric Mann-Whitney test. Numerical data were expressed in frequency and compared using χ2 test. Multiple logistic regression was conducted to identify the factors that influenced the functionality of intestinal mucosal barrier. *P* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

The serum endotoxin \[12.1(4.2\~22.0) vs 3.2(1.3\~6.0), *P* \< 0.001\] and FPG \[(9.8 ± 3.6) vs (5.4 ± 0.7), P \< 0.001\] in patients with T2DM were significantly higher than those in the control group. No significant difference was observed in DAO and D-lactic acid (Table [1](#Tab1){ref-type="table"}).Table 1Background characteristics of particippantsControl groups (n = 33)T2DM (*n* = 66)StatisticsPMale \[n(%)\]19 (57.6)38 (57.6)*--*1.000Age \[(Mean ± SD), years\]61.2 ± 9.660.9 ± 11.8t = 0.1210.904BMI \[(Mean ± SD), Kg/M^2^\]26.5 ± 5.825.1 ± 3.9t = 1.4170.160Smoking \[n(%)\]13 (39.4)16 (24.2)*x*^2^ = 2.4380.118Hypertension \[n(%)\]16 (48.5)40 (60.6)*x*^2^ = 1.3160.251Diabetes history \[(Mean ± SD), years\]NA6.0 (1--14)*--*--Diabetic complication \[n(%)\]NA31 (46.9)*--*--Medications \[n(%)\] InsulinNA21 (31.8)---- MetforminNA32 (48.5)---- α-glucosidase inhibitorNA29 (43.9)---- sulfonylureasNA9 (13.6)---- glinideNA5 (7.6)---- DPP-4 inhibitorNA1 (1.5)----Laboratory data HbAlc \[M(Q1\~Q3), %\]5.2 (4.9\~5.6)9.3 (7.4\~11.0)z = −7.340\< 0.001 GA \[M(Q1\~Q3), %\]14.1 (13.3\~14.8)23.5 (19.4\~28.5)z = −6.751\< 0.001 Creatinine \[M(Q1\~Q3), μmol/L\]76 (64.5\~83)65 (54.5\~80)z = −1.6200.105 GFR \[M(Q1\~Q3), ml/min\]90.3 (83.7\~98.8)94.9 (78.1\~104.1)z = − 0.6720.502 hs-CRP \[M(Q1\~Q3), ng/L\]3 (1.5\~6.7)3.5 (1.2\~18.9)z = −0.8010.423Index of the intestinal mucosal barrier DAO \[M(Q1\~Q3), u/l\]6.7 (5.4\~9.3)5.9 (4.1\~9.6)*z* = −1.4130.158 D-lactic acid \[M(Q1\~Q3), mg/l\]49.0 (43.1\~53.3)47.0 (37.2\~54.8)*z =* −0.5720.567 Endotoxins \[M(Q1\~Q3), μ/l\]3.2 (1.3\~6.0)12.1 (4.2\~22.0)*z* = −4.315\< 0.001FPG\[(Mean ± SD), mmol/l\]5.4 ± 0.79.8 ± 3.6t = −9.070\< 0.001*HbAlc* Glycosylated hemoglobin, *GA* glycated albumin, GFR Glomerular filtration rate, *DAO* diamine oxidase, *hs-CRP* high-sensitivity C-reactive protein, *FPG*:Fasting Plasma Glucose

Clinical charateristics comparation between high- and low-endotoxin groups {#Sec9}
--------------------------------------------------------------------------

The SDBG \[2.9(2.0\~3.3) vs 2.1(1.6\~2.5), *P* = 0.012\] and LAGE \[7.5(5.4\~8.9) vs 5.9(4.3\~7.4), *P* = 0.034\] in the high endotoxin group were higher than those in the low endotoxin group. No significant difference was observed in the other indicators (all *P* \> 0.05) (Table [2](#Tab2){ref-type="table"}).Table 2Between the two groups of clinical data and glucose control comparisonLow groups (\< 12.31u/l, n = 33)High groups (12.31 ≥ u/l, n = 33)StatisticsPMale \[n(%)\]16 (48.5)22 (66.7)*x*^2^ = 2.2330.135Age \[(Mean ± SD), years\]62.3 ± 11.159.5 ± 12.5t = 0.9900.326Hypertension \[n(%)\]21 (63.6)19 (57.6)*x*^2^ = 0.2540.614Smoking \[n(%)\]5 (15.2)11 (33.3)*x*^2^ = 2.9700.085Positive family history \[n(%)\]7 (21.2)7 (21.2)--1.000BMI \[(Mean ± SD), Kg/M^2^\]25.0 ± 4.425.2 ± 3.4t = − 0.1760.861Diabetes history \[(Mean ± SD), mouth\]9.0 (2\~15.5)5.0 (1.0\~10.0)*z* = −1.6490.099hs-CRP \[M(Q1\~Q3), mmol/l\]2.1 (0.5\~6.6)1.8 (0.5\~6.7)*z* = −0.2500.802Medications \[n(%)\] Insulin11.0 (33.3)10.0 (30.3)*x*^2^ = 0.0700.792 Metformin17.0 (51.5)15.0 (45.5)*x*^2^ = 0.2430.622 α-glucosidase inhibitor12.0 (36.4)17.0 (51.5)*x*^2^ = 1.5380.215 Sulfonylureas2.0 (6.1)7.0 (21.2)--0.149 Glinide1.0 (3.0)4.0 (12.1)--0.355 DPP-4 inhibitor0 (0.0)1 (3.0)--1.000Glucose control data FPG \[M(Q1\~Q3), mmol/l\]8.6 (6.8\~12.9)8.8 (7.5\~11.1)*z* = − 0.0230.982 2h PBG \[M(Q1\~Q3), mmol/l\]12.8 (10.6\~18.1)17.0 (15.2\~20.8)*z* = − 1.8580.063 DGA \[M(Q1\~Q3), mmol/l\]11.0 (9.0\~15.0)11.9 (10.1\~13.7)*z* = − 0.3010.763 HbAlc \[M(Q1\~Q3), %\]9.2 (8.2\~10.5)8.2 (8.2\~9.4)*z* = − 1.3200.187 GA \[M(Q1\~Q3), %\]23.3 (19.3\~27.2)25.8 (20.0\~36.3)*z* = − 1.2470.212Glucose fluctuations of Short-term SDBG \[M(Q1\~Q3), mmol/l\]2.1 (1.6\~2.5)2.9 (2.0\~3.3)*z* = − 2.5200.012 PPGE \[M(Q1\~Q3), mmol/l\]2.8 (1.8\~3.1)2.2 (1.9\~3.8)*z* = − 0.9170.359 LAGE \[M(Q1\~Q3), mmol/l\]5.9 (4.3\~7.4)7.5 (5.4\~8.9)*z* = − 2.1230.034 SDBG \< 2.0 mmol/l \[n(%)\]15.0 (45.5)9.0 (27.3)*x*^2^ = 2.3570.125 PPGE \< 2.2 mmol/l \[n(%)\]15.0 (45.5)11.0 (33.3)*x*^2^ = 1.0150.314 LAGE\< 4.4 mmol/l \[n(%)\]9.0 (27.3)4.0 (12.1)*x*^2^ = 2.3950.122*DGA* Daily glucose average,*FPG*:Fasting Plasma Glucose, *PBG*:Postprandial Blood Glucose, *SDBG* Standard Deviation Of Blood Glucose, *PPGE* Postprandial Glucose Excursion, *LAGE* Largest amplitude of glycemic excursions, *BMI* Body Mass Index, *HbAlc* Glycosylated hemoglobin, *GA* glycated albumin, *hs-CRP* high-sensitivity C-reactive protein

Regression analysis {#Sec10}
-------------------

Multivariable linear regression analysis showed that after adjusting for gender, age, and LAGE, SDBG was positively correlated with endotoxin independently (standard partial regression coefficient = 0.255, *P* = 0.039). The scatter-plot is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Scatter plot of the correlation between endotoxin and SDBG. SDBG: Standard Deviation Of Blood Glucose

Discussion {#Sec11}
==========

Previous reports exhibited that patients with T2DM are more susceptible to intestinal mucosal barrier dysfunction \[[@CR23], [@CR24]\], however factors remains to be investigated. In this study, T2DM patients with higher daily blood glucose fluctuation tended to have a higher serum endotoxin level, which indicates the function of the intestinal mucosal barrier was possibly compromised.

In this study patients with T2DM and high SDBG were associated with higher serum endotoxin level; meanwhile there was no significant change in serum DAO and D-lactic acid levels. Diamine oxidase (DAO) is an enzyme mainly produced in the small intestine involved in the histamine metabolism \[[@CR25], [@CR26]\]. Recent studies showed that a established first-line treatment for patients in T2DM, metformin, inhibits DAO activity \[[@CR27]\]. Such inhabitation possibly compensate the increased DAO due to the dysfunction of intestinal mucosal barrier. D-lactate is a bydroxycarboxylic acid produced by bacterial fermentation \[[@CR28], [@CR29]\]. Studies revealed that the gut microbiome composition is altered for T2DM patients treated with metformin \[[@CR30]\], in which possibly explain the inconsistent result in serum D-lactate and endotoxin level.

Endotoxins, also known as Lipopolysaccharides (LPS), are large molecules found in the outer membrane of Gram-negative bacteria. The increase in LPS is associated with bacterial translocation due to the impairment of intestinal epithelial cell \[[@CR31]\]. The increase in endotoxins of T2DM patients are probably result from the change in gut microbial composition, epithelial cell impairment, responses to inflammatory mediators or secondary action of endotoxins \[[@CR31]--[@CR34]\]. A resent study on mice suggested that fluctuant hyperglycemia had more potential to cause oxidative stress and inflammation, and eventually endothelial dysfunction \[[@CR35]\]. In this study, although the amplitude of blood glucose fluctuation of patients are much less than that of mouse model (2.1/2.9 mmol/l vs \~ 15 mmol/l), the SDBG is still an independent factor positively correlated to the serum LPS level. In addition, blood glucose fluctuations are associated with ketoacidosis in patients with DM, and also an independent risk factors for the progression of atherosclerosis \[[@CR4], [@CR36]\]. These pevious reports, combined with this study, further indicate the importance of blood glucose stabilization to health.

Previous studies revealed that T2DM patients are more probably associated with higher LPS, in which long-term hyperglycemia in these patients is one of the causes of intestinal mucosal barrier damage \[[@CR37]\]. The compromised mucosal barrier could be a potential cause of the large blood glucose fluctuartion. In this study, however, no sign of inflammatory damage of intestinal mucosa was observed as the CRP level of patients are at normal level.

Multivariable linear regression analysis revealed that the amplitude of blood glucose fluctuations was an independent risk factor of increased intestinal permeability. The blood glucose fluctuation compromise the intestinal permeability in several possible ways: (1) Increased blood glucose fluctuations affect the integrity of the intestinal epithelial cells and the contact structure between cells \[[@CR38]\]. (2) Abnormal metabolic pathways caused by fluctuations in blood glucose lead to increased inflammatory factors and stimulate intestinal mucosa \[[@CR38]\]. (3) Function of liver is compromised due to the flucturation, thereby preventing timely and effective removal of endotoxins.

The positively correlation between intestinal mucosal barrier damage and SDBG indicates that clinicans/ T2DM patients should carefully maintain stable blood glucose level. Subsequent studies should be done to confirm our findings by increasing the sample size. Although DAO, D-lactic acid, and endotoxin can be used as indicators of the intestinal mucosal barrier status, the impairment mechanism of intestinal mucosal barrier remains to be clearly elucidated. Factors such as intestinal microenvironment affected by medication and immunity of patients should be further investigated.

Conclusions {#Sec12}
===========

In summary, impairment of the intestinal mucosal barrier function, characterized by impaired intestinal permeability, may occur in patients with T2DM with large SDBG. Clinical attention should be focused on monitoring and controlling blood glucose fluctuations in patients with T2DM.
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